{"id":29327,"date":"2014-08-25T08:17:59","date_gmt":"2014-08-25T12:17:59","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=29327"},"modified":"2014-08-25T08:17:59","modified_gmt":"2014-08-25T12:17:59","slug":"aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327","title":{"rendered":"Aastrom Biosciences Inc (NASDAQ:ASTM)\u2019s Results Of Two Phase 2a Trials Published In Journal"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/25\/2014 (wallstreetpr) \u2013<strong> Aastrom Biosciences Inc (NASDAQ:ASTM)<\/strong> announced that <a href=\"http:\/\/money.cnn.com\/news\/newsfeeds\/articles\/globenewswire\/10095729.htm\" target=\"_blank\">results<\/a> of its two Phase 2a trials are published in the journal. The two trials results are of Phase 2a Catheter-DCM Study and IMPACT-DCM study. The phase 2a studies are clinical studies of ixmyelocel-T that is used to treat the advanced heart failure in patients suffering from Ischemic Dilated Cardiomyopathy The results of studies are positive as they reduce the chances of major adverse cardiovascular events in ischemic DCM patients.<\/p>\n<p style=\"text-align: justify;\"><strong>Ixmyelocel-T <\/strong><\/p>\n<p style=\"text-align: justify;\">Ixmyelocel-T is a treatment therapy that uses patient\u2019s bone marrow. Aastrom Biosciences Inc (NASDAQ:ASTM) has got highly automated and fully closed cell processing system that uses the bone marrow to create the multicellular therapy treatment. The objective is to enhance the number of mesenchymal stromal cells and activate macrophages. They are crucial for the growth of anti-inflammatory factors that in turn works for repairing the damaged tissues.<\/p>\n<p style=\"text-align: justify;\"><strong>The open-label studies<\/strong><\/p>\n<p style=\"text-align: justify;\">Aastrom Biosciences Inc (NASDAQ:ASTM) conducted two distinct open-label studies. In all, 61 patients were selected out of which 59 were treated with the standard care. The patients who were given the treatment of ixmyelocel-T showed fewer events of MACE as compared to the control patients. Also, the ischemic DCM patients showed an improvement in the other symptoms.<\/p>\n<p style=\"text-align: justify;\"><strong>The achievement<\/strong><\/p>\n<p style=\"text-align: justify;\">The publication of results in a peer-reviewed journal is an achievement for Aastrom. It validates the results of the study and indicates a positive development in multicellular therapy treatment. Aastrom Biosciences Inc (NASDAQ:ASTM) is looking to conduct a larger, Phase 2b trial which will have a higher number of enrolled patients. The results show a promising future in the use of ixmyelocel-T for treating patients suffering from ischemic dilated Cardiomyopathy. As of now, the patients have to compromise a lot as there are limited treatment options available in the industry. Aastrom is positive on the development program and will make sure to speed it up to reach the final stage of clinical research.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/25\/2014 (wallstreetpr) \u2013 Aastrom Biosciences Inc (NASDAQ:ASTM) announced that results of its two Phase 2a trials are published in the journal. The two [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":17718,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[8319,5352,5353],"stock_ticker":[],"class_list":["post-29327","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-aastrom-biosciences-inc","tag-aastrom-biosciences-inc-nasdaqastm","tag-nasdaqastm","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aastrom Biosciences Inc (NASDAQ:ASTM)\u2019s Results Of Two Phase 2a Trials Published In Journal - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aastrom Biosciences Inc (NASDAQ:ASTM)\u2019s Results Of Two Phase 2a Trials Published In Journal - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/25\/2014 (wallstreetpr) \u2013 Aastrom Biosciences Inc (NASDAQ:ASTM) announced that results of its two Phase 2a trials are published in the journal. The two [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-25T12:17:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Aastrom-Biosciences-Inc.-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"Aastrom Biosciences Inc (NASDAQ:ASTM)\u2019s Results Of Two Phase 2a Trials Published In Journal\",\"datePublished\":\"2014-08-25T12:17:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327\"},\"wordCount\":340,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Aastrom-Biosciences-Inc.-logo.jpg\",\"keywords\":[\"Aastrom Biosciences Inc\",\"Aastrom Biosciences Inc (NASDAQ:ASTM)\",\"NASDAQ:ASTM\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327\",\"name\":\"Aastrom Biosciences Inc (NASDAQ:ASTM)\u2019s Results Of Two Phase 2a Trials Published In Journal - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Aastrom-Biosciences-Inc.-logo.jpg\",\"datePublished\":\"2014-08-25T12:17:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Aastrom-Biosciences-Inc.-logo.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Aastrom-Biosciences-Inc.-logo.jpg\",\"width\":300,\"height\":300},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aastrom Biosciences Inc (NASDAQ:ASTM)\u2019s Results Of Two Phase 2a Trials Published In Journal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aastrom Biosciences Inc (NASDAQ:ASTM)\u2019s Results Of Two Phase 2a Trials Published In Journal - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327","og_locale":"en_US","og_type":"article","og_title":"Aastrom Biosciences Inc (NASDAQ:ASTM)\u2019s Results Of Two Phase 2a Trials Published In Journal - Wall Street PR","og_description":"Boston, MA 08\/25\/2014 (wallstreetpr) \u2013 Aastrom Biosciences Inc (NASDAQ:ASTM) announced that results of its two Phase 2a trials are published in the journal. The two [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-25T12:17:59+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Aastrom-Biosciences-Inc.-logo.jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"Aastrom Biosciences Inc (NASDAQ:ASTM)\u2019s Results Of Two Phase 2a Trials Published In Journal","datePublished":"2014-08-25T12:17:59+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327"},"wordCount":340,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Aastrom-Biosciences-Inc.-logo.jpg","keywords":["Aastrom Biosciences Inc","Aastrom Biosciences Inc (NASDAQ:ASTM)","NASDAQ:ASTM"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327","url":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327","name":"Aastrom Biosciences Inc (NASDAQ:ASTM)\u2019s Results Of Two Phase 2a Trials Published In Journal - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Aastrom-Biosciences-Inc.-logo.jpg","datePublished":"2014-08-25T12:17:59+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Aastrom-Biosciences-Inc.-logo.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Aastrom-Biosciences-Inc.-logo.jpg","width":300,"height":300},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aastrom-biosciences-inc-nasdaqastms-results-of-two-phase-2a-trials-published-in-journal-29327#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Aastrom Biosciences Inc (NASDAQ:ASTM)\u2019s Results Of Two Phase 2a Trials Published In Journal"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/29327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=29327"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/29327\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/17718"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=29327"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=29327"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=29327"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=29327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}